

**MO HEALTHNET DRUG UTILIZATION REVIEW BOARD**

**July 17, 2019**

**Missouri Coalition for Community Behavioral Healthcare, 221 Metro Dr., Lower Level CEO Room, Jefferson City MO**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman Pharm D, Board Chair  
Ginger Nicol, MD, CEDS  
Charlene Heyde, RPh  
Sandra Bollinger, Pharm D  
Glen Talboy, MD  
Stacy Mangum, Pharm D

**DUR BOARD MEMBERS ABSENT**

Jennifer Passanise, FNP  
Kenneth Haller, MD  
Randy Beckner, Pharm D

**OTHERS IN ATTENDANCE**

Mike Lafond, AbbVie  
Audrey Rathan, Alkermes  
Shelley Thompson, Alkermes  
Tom Ranft, Bayer  
Rob Kilo, Biogen  
Aaron, Shaw, Biogen  
Brent Young, GBT  
Erin Hohman, Janssen

David Tritsch Janssen  
Tom Guyer, Lilly  
Jennifer Davis, Kite  
Henrio Thelemaque, MPA  
Marla Wiedermann, Novo Nordisk  
Rick Kegler, Otsuka  
Rob Hansen, Pfizer

**MHD STAFF PRESENT**

Mark Roaseau, R.Ph, Clinical Pharmacist  
Angela Wilson, Pharmacy Operations Manager  
Beth Mitchell, Administrative Office Support Assistant  
Elizabeth Sissom, RN, Clinical Management  
Lisa Hogg, Special Counsel  
Elizabeth Short, Program Specialist  
Dr. Timothy Kling, MD, Assistant Medical Director  
Jackie Hickman, Program Manager

**CONTRACTED STAFF PRESENT**

Joshua Moore, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Janelle Sheen, Pharm D, Conduent  
Emily Oliver, student with Conduent  
Aissa Acelam, student with Conduent  
Chelsea Pendleton, Wipro  
Geri Roling, Wipro

**Drug Utilization Review Board Minutes July 17, 2019**

<b>Preferred Drug List (PDL)</b>	
<b>Opening Remarks</b>	MCO HealthNet Division (MHD). Introductions were made all around.
<b>Minutes Review and Approval</b>	Minutes of the July 2018 DUR Board meeting were reviewed and approved as submitted. (See Roll Call Votes)
<b>Pharmacy Program/Budget Update</b>	Elizabeth Short, Program Specialist, presented a brief power point presentation. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking and State Opioid activities.
<b>Old Business Implementation Schedule</b>	Mark Roaseau discussed the Proposed Implementation Schedule for Edits, including PDL classes being presented for annual review, which was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included March/April, 2019 PDL decisions to be implemented July 2019. Pending ratification, PDL decisions from the June 2019 Drug PA Committee meeting will be implemented October 2019. Schedules may be found on the MHD web page at <a href="https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf">https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf</a>
<b>New Drug Review</b>	Mark Roaseau reviewed the new drug products identified for the quarter January, February, March, 2019 and the recommended status within the clinical program. <ul style="list-style-type: none"> <li>• <b>Discussion</b> - A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet, along with the Drug Prior Authorization Committee's actions/decisions. This listing was also provided to all attending.</li> </ul>
<b>Clinical Edits</b>	
<b>Antianxiety Benzodiazepine Butalbital Combinations without Codeine Butalbital Combinations Excessive Therapy Equetro</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau reviewed the criteria in this new document including the approval and denial criteria.</li> <li>• <b>Public Hearing</b> – no public comment.</li> <li>• <b>Decision</b> – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)</li> </ul>

PDL Edits	
<b>Amylin Analogs</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antihyperuricemic Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Bile Salts Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Bone Ossification Bisphosphonate Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Cephalosporins Antibiotics - Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Colony Stimulating Factors</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>DPP-IV (Dipeptidyl Peptidase-4) Inhibitors</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Electrolyte Depleters</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Fluoroquinolones – Oral</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>GI Antibiotics – Oral:</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>GLP-1 Receptor Agonists (Anti-Diabetic Mimetics)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>

<b>Growth Hormones and Growth Factors</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Hematopoietic Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Hepatitis C Therapy</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Insulins</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Insulins – Long Acting</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Insulins – Mix</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Insulins – Rapid Acting</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Macrolides – Adult</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Macrolides – Pediatric</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Methotrexate Products – Oral and Injectable</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Multiple Sclerosis (MS) Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was tabled for more information. (See Roll Call Votes).</li> </ul>
<b>Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>

<b>Oral Anti-Diabetics: Biguanides</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Oral Anti-Diabetics: Combinations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Oral Anti-Diabetics: Meglitinides</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Oral Anti-Diabetics: Sulfonylureas 2nd Gen</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Oral Anti-Diabetics: Thiazolidinediones</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Penicillins</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Sodium-Glucose Co- Transporter 2 (SGLT2)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Targeted Immune Modulators</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Tetracyclines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Urinary Tract Antispasmodics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Vaginal Antibiotics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Roaseau presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>

<b>Clinical Edit Summary Report Call Center Statistics</b>	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Luke Boehmer reviewed how many sites/physical locations are trained and have access to Cyber Access. Reports also detailed the number and type of prescribers and active users on Cyber Access.
<b>Conduent Update</b>	Luke Boehmer, Pharm D, presented the following items for review. The Call Center Statistics, Claims, Spend, and Diagnosis information for the SSRI's and SNRI's. Dr. Boehmer also presented an updated analysis of the Opioid Edits that included the distinct members over 90 MME and also the number of opioid naïve participants that we currently have over 50 MME without a PA. Lastly, Dr. Boehmer presented the New Drug Summary,
<b>Preferred Drug List Announcement</b>	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. There was a verbal add in of ADHD that was agreed upon by the board. This handout was also provided to all attendees and will be posted to the Division's web page: <a href="http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf">http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</a>
<b>Program Utilization: Top 25 Drugs Summary</b>	Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2 <sup>nd</sup> , 3 <sup>rd</sup> , & 4th quarter 2017. It was noticed that our reports in the packets were incorrect and the board will be emailed the correct ones for future review. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
<b>Adjourn</b>	Ginger Nicol made a motion to move to close the meeting under Section 610.021 (5), (14) to go into Executive Session for the sole purpose of discussing individual participant specific medical information. (See attached roll call vote). At the conclusion of this discussion the meeting was adjourned entertaining no further business, actions, or motions. (See attached roll call vote). The next DUR Board meeting is scheduled for October 16, 2019, at the <b>Missouri Coalition for Community Behavioral Healthcare, Lower Level CEO Room, 221 Metro Drive , Jefferson City MO.</b>

**Roll Call Votes – July 17, 2019**

<b><u>Roll Call for July 17,</u></b> <b><u>2019</u></b>				
--	--	--	--	--

<u>Member</u>	Minutes July 2018	All Recommendations Block Vote for October 2018	CLOSE SESSION PURSUANT TO SECTION 610.021 Subsection (14).(5)	ADJOURN
Susan Abdel-Rahman	Y	Y		
Charlene Heyde	SY	SY		
Sandra Bollinger	Y	Y		
Kenneth Haller	A	A		
Glen Talboy	MY	Y		
Jennifer Passanise	A	A		
Stacy Mangum	Y	MY		
Ginger Nicol	Y	Y		
Randy Becker	A	A		
<u>Member</u>	Minutes	All Recommendations Block Vote January 2019	CLOSE SESSION PURSUANT TO SECTION 610.021 Subsection (14).(5)	ADJOURN
Susan Abdel-Rahman		Y		
Charlene Heyde		Y		
Sandra Bollinger		SY		
Kenneth Haller		A		
Glen Talboy		Y		
Jennifer Passanise		A		
Stacy Mangum		MY		
Ginger Nicol		Y		
Randy Becker		A		

<u>Member</u>	Minutes	All Recommendations Block Vote April 2019	CLOSE SESSION PURSUANT TO SECTION 610.021 Subsection (14).(5)	ADJOURN
Susan Abdel-Rahman		Y		
Charlene Heyde		MY		
Sandra Bollinger		Y		
Kenneth Haller		A		
Glen Talboy		SY		
Jennifer Passanise		A		
Stacy Mangum		Y		
Ginger Nicol		Y		
Randy Becker		A		
<u>Member</u>	Minutes	All Recommendations Block Vote July 2019	CLOSE SESSION PURSUANT TO SECTION 610.021 Subsection (14).(5)	ADJOURN
Susan Abdel-Rahman		Y	Y	
Charlene Heyde		SY	SY	
Sandra Bollinger		MY	Y	
Kenneth Haller		A	A	
Glen Talboy		Y	Y	
Jennifer Passanise		A	A	
Stacy Mangum		Y	Y	
Ginger Nicol		Y	MY	
Randy Becker		A	A	



**M - Motion to vote**  
**S - Second to vote**  
**Y - Yes to the vote**  
**N - No to the vote**  
**A - Absent**  
**AB - Abstain vote**

**EXECUTIVE SESSION**  
**July 17, 2019**

**DUR BOARD MEMBERS PRESENT**

Ginger Nicol, MD, CEDS-filled in as Board Chair  
Charlene Heyde, RPh  
Sandra Bollinger, Pharm D  
Randy Beckner, Pharm D  
Glen Talboy, MD  
Kenneth Haller, MD  
Jennifer Passanise, FNP

**DUR BOARD MEMBERS ABSENT**

Susan Abdel-Rahman, Pharm D – Board Chair  
Stacy Mangum, Pharm D

**MHD STAFF PRESENT**

Mark Roaseau, RPh, Clinical Pharmacist  
Sharie Hahn, Special Council  
Angela Wilson, Program Developmental Specialist  
Elizabeth Sissom, RN, Clinical Management  
Lisa Smith, Program Development Specialist  
Mitch Ruth, Pharmacy Fiscal Unit Manager  
Frances (Franki) Moseley, Administrative Office Support Assistant  
Dr. Timothy Kling, MD, Assistant Medical Director

**CONTRACTED STAFF PRESENT**

Joshua Moore, Pharm D, Conduent  
Katie Wilburs, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Janelle Sheen, Pharm D, Conduent  
Chelsea Pendleton, Wipro  
Geri Roling, Wipro

Minutes Review	There were no January minutes for the Executive Session to be approved as submitted.
Case Reviews	No Case for Review
Adjourn	Executive session